Back to search results
NCT06084533

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Enrolling by Invitation
Not specifiedAges 50+Observational
Washington University School of Medicine
~80 participants
Updated 2026-04-02 on ClinicalTrials.gov
What's tested:[11C]-CS1P1

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.
Measured over At the time of PET scan

Conditions

Parkinson Disease

Explore related trials

Parkinson Disease

NCT06084533

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Washington University School of Medicine

    St Louis, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Robert L White, MD, PhD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion

any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
history of brain surgery or major head trauma
major medical/systemic illness
severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
major drug abuse
history of long term use of anti-dopaminergic medication
chronic treatment with immunomodulatory or anti-inflammatory medications
weight over 300 lbs
contraindication to or inability to tolerate MRI

What this trial measures

  • PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.At the time of PET scan

    The investigators hypothesize that specific binding of \[11C\]-CS1P1 is elevated in participants with neurodegenerative disease of the central nervous system compared to healthy control participants.